Brainomix and Endeavor BioMedicines Present Positive Results from Quantitative Image Analysis of Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Trial at ERS Congress

• AI-powered quantitative CT analysis with Brainomix 360 e-Lung was used in Endeavor BioMedicines ENV-IPF-101 Phase 2a trial of taladegib. Results identified significant treatment effects across multiple measures of lung structure and fibrosis.
• Findings highlight the potential of sensitive imaging biomarkers to support clinical development in pulmonary fibrosis
• Positive results pave the way for further collaboration between Brainomix and Endeavor to advance taladegib development

OXFORD, England and CHICAGO, Sept. 8, 2026 /PRNewswire/ -- Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, and Endeavor BioMedicines, a clinical-stage biotechnology company, presented positive results from the Brainomix AI-driven quantitative analysis of HRCT imaging data in Endeavor's Phase 2a trial of taladegib in idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society (ERS) Conference in Barcelona.

The randomized, double-blind, placebo-controlled 12-week study evaluated taladegib, a hedgehog pathway inhibitor in patients with IPF. The trial previously demonstrated that treatment with taladegib improved lung function from baseline as measured by forced vital capacity (FVC), increased total lung capacity and reversed measures of interstitial lung disease (ILD) from baseline at Week 12.

Brainomix 360 e-Lung is an FDA-cleared, CE-marked AI-powered image analysis tool that provides automatic quantifications and visualizations of radiographic features in lung CT scans. Clinicians can use these outputs to aid in their diagnostic assessment of lung disease.

Brainomix and Endeavor entered into a collaboration to conduct a post-hoc analysis evaluating the potential of Brainomix AI-powered quantitative imaging outputs to support clinical trials.  Trained on diverse datasets, the platform has already been employed in several Phase 2 and Phase 3 trials and became the first quantitative CT imaging platform selected as a co-primary endpoint in a Phase 3b pulmonary fibrosis trial.

In a post-hoc analysis of the 12-week Phase 2a ENV-IPF-101 trial, e-Lung quantitative CT imaging was used. Analysis by the authors detected significant positive differences in favor of taladegib in lung volume, overall ILD burden and total fibrosis extent.

These findings highlight the potential of AI-powered quantitative imaging outputs to support the detection of meaningful treatment effects in small, relatively short clinical studies, supporting more efficient and informed clinical development.

Importantly, these results highlight the value of reliable, objective AI-endpoints in clinical development programmes for pulmonary fibrosis. While forced vital capacity (FVC) remains an established clinical endpoint, it may not fully capture meaningful biological changes or provide mechanistic insights into treatment response. As background therapies reduce measurable declines in lung function, increasingly sensitive CT quantification results may help detect subtle treatment effects and support more efficient, data-informed drug development.

These positive results have catalyzed further collaboration between Brainomix and Endeavor BioMedicines, aiming to incorporate quantitative image analysis into the further clinical development of taladegib for pulmonary fibrosis.

Dr Lisa Lancaster, Chief Medical Officer at Endeavor BioMedicines, commented: "The results of Brainomix's post hoc quantitative imaging analysis continue to support taladegib's potential to improve lung structure, reduce fibrosis and improve lung function in patients with IPF. We are impressed with the technology's ability to detect statistically significant changes in a small cohort and over a short treatment duration. These results are a testament to the value of objective, sensitive and reliable endpoints for the de-risking of clinical development, and we look forward to future collaboration opportunities with Brainomix."

Professor Peter George, Consultant Pulmonologist at the Royal Brompton Hospital, UK, and Senior Medical Director at Brainomix, added: "Our goal is to accelerate the clinical development of potentially transformational treatments, and taladegib is one of the most promising therapies for pulmonary fibrosis currently in development. We are very pleased to see that our analysis with e-Lung was able to provide key insights into the efficacy and mechanism of taladegib. Quantitative CT imaging offers a powerful approach to support earlier, faster, and more informed development decisions, ultimately helping promising therapies reach patients sooner."

Brainomix is also presenting four additional studies at ERS 2026 demonstrating the potential of quantitative CT to provide objective insights in the assessment of pulmonary CT scans. The studies explored topics around assessing ILD treatment responses, detecting early disease progression, stratifying the risk of mortality and identifying patients at risk of pulmonary hypertension.

About Brainomix

Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung diseases. Its flagship product, Brainomix 360 Stroke, is the world's first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung is an FDA-cleared, CE-marked AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans using a configured clinical workflow. Quantification of CT features can enable clinicians to more easily identify visual changes over multiple timepoints. Founded as a spinout from the University of Oxford, Brainomix has offices in the UK, Ireland and the USA, and operations in more than 20 countries.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on LinkedIn, X, and Facebook.

Contacts

At the company
Jeff Wyrtzen, Chief Marketing Officer
jwyrtzen@brainomix.com
T +44 (0)1865 582730

Media Enquiries

USA
Jordyn Temperato
LifeSci Communications
BrainomixMedia@lifescicomms.com 

UK & Europe Media Enquiries
Sue Charles
Charles Consultants
sue@charles-consultants.com